A double-blind and randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep vein thrombosis in acute ischemic stroke

Department of Medicine, Aker University Hospital, Oslo, Norway.
Seminars in Thrombosis and Hemostasis (Impact Factor: 3.88). 11/1990; 16 Suppl:25-33.
Source: PubMed


The effect of LMW heparin (Kabi 2165, Fragmin) was compared with placebo for the prevention of DVT in 103 patients with acute ischemic stroke using a prospective, double-blind, randomized trial design. Treatment was started within 72 hours, and LMW heparin was administered subcutaneously once daily according to body weight classes, which corresponded to about 55 to 65 Factor-Xa inhibitory U/kg, for 14 days, or until discharge from the hospital, if earlier. All patients underwent thrombosis surveillance with unilateral venography of the paretic limb. Evaluation of venography could be performed in 42 of 52 patients randomized to LMW heparin and in 50 of 51 patients randomized to placebo. The frequency of DVT was 15 of 42 patients or 36% (95% confidence interval 22 to 52%) in the LMW heparin group and 17 of 50 patients or 34% (21 to 49%) in the placebo group. The frequency of proximal thrombi was 5 of 42 (12%) and 8 of 50 (16%), respectively. There was one fatal pulmonary embolism in the placebo group. The mortality rate (28 days follow-up) was 5 of 52 in the LMW heparin group and 1 of 51 in the placebo group (p = 0.24). None of the deaths was related to treatment. No major hemorrhagic complications were observed. The mean Factor Xa inhibitory activity levels at peak concentration were 0.34 U/ml on day 2 and 0.42 U/ml on day 12 (p = 0.02). We conclude that LMW heparin in the dose range studied did not provide efficient prophylaxis against DVT in patients with acute ischemic stroke.

2 Reads
  • Source
    • "Risk Ratio (95% CI) Weight, % Study PE Risk Ratio 7.5 8.2 5.0 3.8 46.9 3.8 10.0 15.0 0.10 (0.01-2.05) 0.50 (0.05-5.22) 0.33 (0.01-7.85) 0.31 (0.14-0.71) 0.33 (0.01-8.04) 0.17 (0.02-1.59) 0.83 (0.25-2.70) 0.37 (0.21-0.64) Turpie et al, 40 1987 Prins et al, 41 1989 Sandset et al, 42 1990 Hommel et al, 45 1998 TOAST, 46 1998 Samama et al, 47 1999 Leizorovicz et al, 49 2004 "
    [Show abstract] [Hide abstract]
    ABSTRACT: In the last decade, greater focus has been directed toward venous thromboembolism (VTE) prophylaxis in hospitalized, non-surgical patients. Both deep venous thrombosis and pulmonary embolism are potentially preventable causes of patient morbidity and mortality related to hospitalization. Despite the availability of high-quality, evidence-based guidelines for VTE prevention, there is compelling evidence that many hospitalized patients do not receive appropriate VTE prevention measures. Hospitalists play an important role in the implementation of appropriate VTE prophylaxis measures for this patient population; thus, knowledge of updated recommendations is vital to their practice, as well as patient safety. We provide a comprehensive evidence-based clinical review of VTE prophylaxis for nonsurgical hospitalized patients, including risk factors and risk assessment, indications for prophylaxis, recommended therapeutic options, and updates from recently released practice guidelines by the American College of Physicians and the American College of Chest Physicians, published in 2011 and 2012, respectively.
    Hospital practice (1995) 08/2013; 41(3):60-9. DOI:10.3810/hp.2013.08.1069
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: RESUMEN OBJETIVO: Valorar la seguridad de no anticoagular a los pacientes con sospecha de embolia pulmonar aguda, después de una arteriografía pulmonar y una venografía de miembros inferiores por tomografía computarizada multicorte (TCMC) negativa. MATERIAL Y MÉTODOS: Es un estudio prospectivo realizado en el Hospital la Fe incluyendo de forma consecutiva, entre agosto del 2001 y noviembre del 2004, todos los pacientes con sospecha de embolia pulmonar aguda. Se ha utilizado la TCMC como la técnica diagnóstica de elección, aunque también se ha realizado en cada paciente una gammagrafía pulmonar y una ecografía de los miembros inferiores. Estas 3 pruebas diagnósticas se han realizado en las primeras 72 horas desde la sospecha de la enfermedad. En todos los pacientes con un estudio de TCMC negativa y que fueron anticoagulados, se realizó un seguimiento de 6 meses para descartar episodios de embolia pulmonar o trombosis venosa durante ese periodo de seguimiento. RESULTADOS: Se han incluido 383 pacientes consecutivos con sospecha de embolia pulmonar aguda. El resultado de la prueba de TCMC ha sido positiva en 156 pacientes (por embolia pulmonar, trombosis venosa o ambas), en 224 pacientes ha sido negativa y 3 casos indeterminada. Los falsos negativos de la técnica han sido: 1 caso de recidiva de embolia pulmonar detectado durante el seguimiento, además de 5 casos de gammagrafía pulmonar de alta probabilidad y 2 casos de trombosis venosa detectados en la ecografía de miembros inferiores. El valor predictivo negativo obtenido para la arteriografía pulmonar y la venografía de miembros inferiores por TCMC ha sido del 95,8% y su sensibilidad del 95,1%. El porcentaje de recidivas tras una TCMC negativa ha sido, tan sólo, del 0,5%. El 5% (19/380) de los pacientes del estudio presentó tromboembolismo venoso con signos de trombosis en los miembros inferiores pero sin signos de embolia pulmonar. CONCLUSIONES: La arteriografía pulmonar y la venografía de los miembros inferiores realizada por TCMC, es una técnica eficaz en el diagnóstico de la embolia pulmonar. El valor predictivo negativo de esta técnica es muy alto y el porcentaje de recidivas tras un estudio negativo es muy bajo. Esto demuestra que es suficientemente seguro no anticoagular a los pacientes con sospecha de embolia pulmonar tras un estudio de TCMC negativa, sin necesidad de realizar otras pruebas diagnósticas. La venografía de miembros inferiores realizada adicionalmente a la arteriografía pulmonar por TCMC, ha demostrado aumentar la sensibilidad de la prueba del 83,5% al 95,1%. Esto indica que es necesario combinar el estudio de las arterias pulmonares por TCMC con un estudio de los miembros inferiores, ya sea realizado por venografía por TCMC o por ecografía, para obtener una segura y elevada sensibilidad de esta prueba en los pacientes con sospecha de embolia pulmonar. __________________________________________________________________________________________________ Purpose: To evaluate the safety of withholding anticoagulation in patients with suspected acute pulmonary embolism after negative multislice computed tomography (MSCT) pulmonary angiography and lower-limb venography. Materials and methods: A total of 383 consecutive patients with suspected acute pulmonary embolism were prospectively studied. Patients underwent MSCT pulmonary angiography and lower-limb venography, as well as pulmonary scintigraphy and lower-limb ultrasound examination. Patients with negative MSCT results for both pulmonary embolism and venous thrombosis were not administered anticoagulants and were followed up for 6 months to rule out thromboembolism. Results: At MSCT, 156 patients were positive for pulmonary embolism, venous thrombosis, or both; 224 were negative; and findings were inconclusive in three. False-negatives were five patients with high probability scintigram and two with venous thrombosis detected at US. A total of 184 patients with negative MSCT and without anticoagulation were followed up for 6 months. During this period of time just one recurrence of pulmonary embolism was detected. The negative predictive value of MSCT pulmonary angiography plus lower-limb venography was 95.8% (183/191). Conclusion: MSCT is efficacious in diagnosing pulmonary embolism, with negative predictive values reported in the literature ranging from 94% to 100%. This enables omission of anticoagulation in patients with suspected pulmonary embolism after negative MSCT findings without the need for other diagnostic tests.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Hemorrhagic transformation of cerebral infarction (HTI) occurs spontaneously but its frequency and risk factors are uncertain with mixed results in previous studies. We aimed to determine the overall frequency of and risk factors for HTI. We performed a systematic review according to Cochrane Collaboration methods of published reports of HTI with reliable, systematic follow-up with computed tomography or magnetic resonance imaging. In all, 28 observational studies and 19 randomized controlled trials in stroke were identified that included follow-up imaging data. Problems with inconsistent definitions or small and biased patient populations limited detailed interpretation. The overall frequency of any HTI in untreated patients was 8.5% (95% confidence interval 7%-10%). Severe HTI (i.e., HTI accompanied by neurologic deterioration or parenchymal hematoma formation) occurred in 1.5% (95% confidence interval 0.8%-2.2%). The frequency of HTI increased markedly with increasing use of antithrombotic or thrombolytic drugs. Magnetic resonance imaging detected more HTI than did computed tomography. The published data were generally inadequate to undertake more detailed analysis of risk factors. However, in the 8 studies that did provide the information, HTI was associated with large infarcts, mass effect, hypodensity observed early after the stroke, and age older than 70 years, but not hypertension or cardioembolic stroke. Severe HTI is uncommon in patients not receiving antithrombotic or thrombolytic agents. The methods used to assess the frequency of and risk factors for HTI, particularly a standard of definitions in future prospective studies, could be improved.
    Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association 11/2004; 13(6):235-46. DOI:10.1016/j.jstrokecerebrovasdis.2004.03.003 · 1.67 Impact Factor
Show more